Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nuvelo, a biopharmaceutical company, has announced positive results from the Phase I trial of recombinant, secreted protein, NU206, the company's lead compound from its Wnt Therapeutics Program.
Subscribe to our email newsletter
This single-center, double-blind, placebo-controlled, single-ascending dose trial tested the safety, tolerance and pharmacokinetics of a single intravenous administration of NU206, in 32 healthy male volunteers.
Participants were enrolled in four cohorts of varying doses, with a maximum dose of 0.20mg/kg/day. NU206 had a favorable safety profile, no serious adverse events were observed, and pharmacokinetics were predictable, the company said.
Ted Love, chairman and CEO of Nuvelo, said: “Based on preclinical studies, we believe that NU206 promotes cell growth and repair, and, based also on results from this Phase I trial, believe it has the potential to offer a novel approach for the treatment of serious medical conditions such as gastrointestinal injury, inflammatory bowel disease, and bone disease.
“Because Nuvelo is in the process of merging with Arca biopharma to create a cardiovascular-focused company, we are currently evaluating partnership and out-licensing opportunities for NU206 to continue development of the compound.”